Compare iShares MSCI Japan ETF (EWJ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares MSCI Japan ETF trades at $97.7, while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: iShares MSCI Japan ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| EWJ | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $96.97 | $164.28 |
52-Week Low | $77.93 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.68, up 1.7% on the day, with a bullish technical signal driven by moving averages. The ETF's performance is influenced by Japan's economic policies, including recent U.S.-Japan yen intervention and domestic stimulus efforts. Key support sits at $96, while resistance is at $97, with the RSI indicating potential overbought conditions.
Outlook remains tied to Japan's economic reforms and currency stability, offering exposure to Japanese equities but with risks from yen volatility and inflation. Investor sentiment is cautious amid BOJ policy uncertainty, though institutional interest persists for diversification benefits.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
